BR112018005208A2 - Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana - Google Patents

Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana

Info

Publication number
BR112018005208A2
BR112018005208A2 BR112018005208A BR112018005208A BR112018005208A2 BR 112018005208 A2 BR112018005208 A2 BR 112018005208A2 BR 112018005208 A BR112018005208 A BR 112018005208A BR 112018005208 A BR112018005208 A BR 112018005208A BR 112018005208 A2 BR112018005208 A2 BR 112018005208A2
Authority
BR
Brazil
Prior art keywords
compounds containing
heterocyclic compounds
compositions useful
mycobacterial infection
useful against
Prior art date
Application number
BR112018005208A
Other languages
English (en)
Other versions
BR112018005208B1 (pt
Inventor
Marvin J Miller
Garrett Moraski
Original Assignee
Marvin J Miller
Garrett Moraski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marvin J Miller, Garrett Moraski filed Critical Marvin J Miller
Publication of BR112018005208A2 publication Critical patent/BR112018005208A2/pt
Publication of BR112018005208B1 publication Critical patent/BR112018005208B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
BR112018005208-6A 2015-09-17 2016-09-19 Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana BR112018005208B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562220192P 2015-09-17 2015-09-17
US62/220,192 2015-09-17
PCT/US2016/052558 WO2017049321A1 (en) 2015-09-17 2016-09-19 Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection

Publications (2)

Publication Number Publication Date
BR112018005208A2 true BR112018005208A2 (pt) 2018-10-02
BR112018005208B1 BR112018005208B1 (pt) 2023-12-12

Family

ID=58289763

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018005208-6A BR112018005208B1 (pt) 2015-09-17 2016-09-19 Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana

Country Status (15)

Country Link
US (2) US10919888B2 (pt)
EP (1) EP3328382A4 (pt)
JP (1) JP7055378B2 (pt)
KR (1) KR20180053386A (pt)
CN (1) CN108348510B (pt)
AU (2) AU2016324598A1 (pt)
BR (1) BR112018005208B1 (pt)
CA (1) CA2998375A1 (pt)
CL (1) CL2018000688A1 (pt)
HK (1) HK1252225A1 (pt)
IL (1) IL257743B (pt)
MX (2) MX2018003294A (pt)
PE (1) PE20181352A1 (pt)
WO (1) WO2017049321A1 (pt)
ZA (1) ZA201802323B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3328382A4 (en) 2015-09-17 2018-12-19 Marvin J. Miller Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
EP3464272B1 (en) 2016-06-07 2021-12-08 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
KR102317480B1 (ko) 2017-03-23 2021-10-25 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN108159049B (zh) * 2018-02-01 2021-01-05 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
JP2022536043A (ja) * 2019-05-28 2022-08-12 塩野義製薬株式会社 シトクロムbc1阻害剤とクラリスロマイシン又はアジスロマイシン及びクロファジミンを組み合わせることを特徴とするマイコバクテリア感染症治療用医薬
TW202124379A (zh) * 2019-09-10 2021-07-01 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的5,6-雜芳族化合物
CN114423758A (zh) * 2019-09-13 2022-04-29 爱尔兰詹森科学公司 抗细菌化合物
KR20220070489A (ko) * 2019-09-26 2022-05-31 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 티아졸 카복사미드 화합물 및 미코박테리아 감염의 치료를 위한 이의 용도
WO2022119899A1 (en) * 2020-12-02 2022-06-09 Shionogi & Co., Ltd. A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin
WO2022194803A1 (en) * 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525602A1 (fr) 1982-04-21 1983-10-28 Synthelabo Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
FR2593818B1 (fr) 1986-02-05 1988-04-29 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
DE4010797A1 (de) 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
DE4023215A1 (de) 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
JPH0539205A (ja) 1990-12-21 1993-02-19 Takeda Chem Ind Ltd 農園芸用混合組成物
JP3026845B2 (ja) 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
US5464843A (en) 1992-06-23 1995-11-07 G.D. Searle & Co. Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury
US5721273A (en) 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
AU2223495A (en) 1994-04-15 1995-11-10 Yamanouchi Pharmaceutical Co., Ltd. Spiro compound and medicinal composition thereof
EP0771319A1 (en) 1994-07-15 1997-05-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
JPH09249666A (ja) 1996-01-12 1997-09-22 Takeda Chem Ind Ltd 三環性化合物の製造法およびその中間体
AU8096798A (en) 1997-06-27 1999-01-19 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
AUPP278498A0 (en) 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
WO1999063929A2 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
HUP0203954A2 (hu) 1999-09-17 2003-03-28 Millennium Pharmaceuticals, Inc. Xa faktor inhibitorok
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
DK1277754T3 (da) 2000-04-27 2005-11-14 Astellas Pharma Inc Imidazopyridinderivater
US6552037B2 (en) 2000-06-30 2003-04-22 Neurogen Corporation 2-Substituted imidazo[1,2-A]pyridine derivatives
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
DE10247269A1 (de) 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
US20050113576A1 (en) 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
UA82577C2 (en) 2003-12-23 2008-04-25 Пфайзер Инк. Quinoline derivatives
WO2005108399A1 (ja) 2004-05-10 2005-11-17 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン化合物
US20060084806A1 (en) 2004-07-21 2006-04-20 Ramasubramanian Sridharan Processes for the preparation of imidazo[1,2-a] pyridine derivatives
EP1778685B1 (de) 2004-08-02 2008-03-26 Schwarz Pharma Ag Carboxamide des indolizins und seiner aza- und diazaderivate
WO2006051063A1 (en) 2004-11-11 2006-05-18 Ferrer Internacional S. A. Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto
DE102005016547A1 (de) * 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2007018998A2 (en) 2005-08-05 2007-02-15 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
AU2007254361A1 (en) 2006-05-18 2007-11-29 Merck Sharp & Dohme Corp. Substituted esters as Cannabinoid-1 receptor modulators
WO2008038251A2 (en) 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
CN101553224A (zh) 2006-10-06 2009-10-07 艾博特公司 新型咪唑并噻唑和咪唑并唑
JP2010513272A (ja) 2006-12-14 2010-04-30 メルク エンド カムパニー インコーポレーテッド アシルビピペリジニル化合物、そのような化合物を含む組成物、及び治療方法
CA2672960A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
WO2008109177A2 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
EP1980251A1 (en) 2007-04-13 2008-10-15 Glaxo Group Limited Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis
TW200901969A (en) 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
WO2009015208A1 (en) 2007-07-23 2009-01-29 Replidyne, Inc. Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
AU2009208712B2 (en) 2008-02-01 2013-03-14 Orchid Chemicals & Pharmaceuticals Limited Novel heterocycles
CA2724842A1 (en) 2008-05-19 2009-11-26 Sunovion Pharmaceuticals Inc. Imidazo[1,2-a]pyridine compounds
WO2009148961A2 (en) 2008-05-29 2009-12-10 Wisconsin Alumni Research Foundation Drugs to prevent hpv infection
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2010064020A1 (en) 2008-12-04 2010-06-10 Proximagen Ltd. Imidazopyridine compounds
CA2750635A1 (en) 2009-02-23 2010-08-26 Merck Canada Inc. Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2401275B1 (en) 2009-02-24 2013-07-24 Respiratorius AB Naphthyridine derivatives having bronchodilating activity
CA2772714C (en) 2009-09-03 2017-09-26 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
IN2012DN04917A (pt) 2009-11-05 2015-09-25 Univ Notre Dame Du Lac
CN102869661B (zh) 2010-03-18 2015-08-05 韩国巴斯德研究所 抗感染化合物
EA022164B1 (ru) 2011-02-25 2015-11-30 Янссен Фармацевтика Нв (ПИРИДИН-4-ИЛ)БЕНЗИЛАМИДЫ КАК АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ АЛЬФА 7 nAChR
KR20140093610A (ko) 2011-04-21 2014-07-28 재단법인 한국파스퇴르연구소 소염 화합물
CA2836202A1 (en) * 2011-05-30 2012-12-06 Astellas Pharma Inc. Imidazopyridine compounds
BR112014010368A2 (pt) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
WO2014015167A2 (en) 2012-07-18 2014-01-23 University Of Notre Dame Du Lac 5,5-heteroaromatic anti-infective compounds
CA2891926A1 (en) 2012-11-20 2014-05-30 Merial, Inc. Anthelmintic compounds and compositions and method of using thereof
CA2891976C (en) * 2012-11-30 2020-07-21 Astellas Pharma Inc. Imidazopyridine compounds
ES2883565T3 (es) 2013-08-02 2021-12-09 Pasteur Institut Korea Compuestos antiinfecciosos
CN105524058B (zh) 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
EP3316969B1 (en) 2015-07-02 2022-03-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP3328382A4 (en) 2015-09-17 2018-12-19 Marvin J. Miller Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
EP3472158A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
MX2018015657A (es) 2016-06-16 2019-03-14 Janssen Sciences Ireland Unlimited Co Compuestos heterociclico como antibacterianos.
EP3266454A1 (en) 2016-07-07 2018-01-10 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Acc inhibitors for use in treating mycobacterial diseases
EP3589323B1 (en) 2017-03-01 2024-04-03 Janssen Sciences Ireland Unlimited Company Combination therapy for the treatment of tuberculosis
CN108159049B (zh) 2018-02-01 2021-01-05 中国科学院广州生物医药与健康研究院 一种吡啶类化合物的新用途
US20210009583A1 (en) 2018-03-12 2021-01-14 University Of Notre Dame Du Lac Deuterated imidazopyridines
CN108358917B (zh) 2018-04-24 2020-06-19 北京市结核病胸部肿瘤研究所 含有碱性稠环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法
CN114423758A (zh) 2019-09-13 2022-04-29 爱尔兰詹森科学公司 抗细菌化合物

Also Published As

Publication number Publication date
CL2018000688A1 (es) 2018-11-16
CA2998375A1 (en) 2017-03-23
IL257743A (en) 2018-04-30
RU2018111768A3 (pt) 2020-02-20
US10919888B2 (en) 2021-02-16
AU2016324598A1 (en) 2018-03-15
JP2018532723A (ja) 2018-11-08
BR112018005208B1 (pt) 2023-12-12
CN108348510A (zh) 2018-07-31
CN108348510B (zh) 2022-01-04
US20210198254A1 (en) 2021-07-01
WO2017049321A1 (en) 2017-03-23
MX2021000189A (es) 2021-03-25
EP3328382A4 (en) 2018-12-19
JP7055378B2 (ja) 2022-04-18
HK1252225A1 (zh) 2019-05-24
MX2018003294A (es) 2019-04-25
ZA201802323B (en) 2019-01-30
RU2018111768A (ru) 2019-10-17
KR20180053386A (ko) 2018-05-21
IL257743B (en) 2022-08-01
EP3328382A1 (en) 2018-06-06
US11820767B2 (en) 2023-11-21
US20180265506A1 (en) 2018-09-20
PE20181352A1 (es) 2018-08-22
AU2021203931A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
BR112018005208A2 (pt) Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana
ES2964472T3 (es) Composiciones que contienen ibrutinib
BR112017000039A2 (pt) composições agrícolas e aplicações que utilizam óleos essenciais
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3182962T3 (da) Compositions and uses of amidine derivatives
DK3416996T3 (da) Hærdelig sammensætning
DK3359241T3 (da) Formuleringer af pthrp-analoger, transdermale plastre deraf og anvendelser deraf
BR112017016465A2 (pt) composto heterocíclico e composição farmacêutica que o compreende
DK3388427T3 (da) Derivater af dolastatin 10 og auristatiner
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3083683T3 (da) Sammensætninger og fremgangsmåder til behandling af fedtvævsansamlinger
DK2777689T3 (da) Ny farmaceutisk sammensætning til behandling af svampeinfektioner
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
IL271550B (en) A cyclic coumarin-like compound as a mek inhibitor and its use
DK3411008T3 (da) Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren
EP3237413A4 (en) Compositions of fatostatin based heterocyclic compounds and uses thereof
MA43166A (fr) Formulation de fviii
DK3436029T3 (da) Forbindelse indeholdende dexpanthenolglycosid
KR20180084930A (ko) 접착제 조성물 및 구조체
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
DK3171873T3 (da) Sammensætning omfattende en ester af alfa-tocopherol til forebyggelse og behandling af allergisk rhinitis
TWI839336B (zh) 活性能量射線硬化性剝離型黏著劑組成物
DK3654973T3 (da) Sammensætninger mod candida-infektioner
DE112017004024A5 (de) Silikonzusammensetzung

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/09/2016, OBSERVADAS AS CONDICOES LEGAIS